New List: The FCPA Top 40
Richard L. Cassin
December 12, 2019
Here’s the FCPA Blog’s list of the 40 biggest Foreign Corrupt Practices Act resolutions of all time.… Continue Reading
Editors
Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
Posts Tagged: Bio-Rad
Here’s what the Bio-Rad ruling means for FCPA retaliation
Bill Steinman
March 6, 2019
Federal court opinions interpreting the FCPA are rare indeed — my informal tally puts the number at a dozen or so since 1977. This week, that number increased by one, thanks to the 9th Circuit’s opinion in Wadler v.… Continue Reading
Practice Note: How Bio-Rad’s old FCPA settlement became a ‘risk factor’
Richard L. Cassin
May 15, 2017
You would expect investors to be pleased and optimist when their company resolves an FCPA case by paying relatively moderate penalties and landing a DOJ non-prosecution agreement.
Good news, the dark cloud is gone.… Continue Reading
FCPA whistleblower: Former Bio-Rad GC awarded $10 million for retaliatory firing
Richard L. Cassin
February 7, 2017
A federal jury in San Francisco took just three hours Monday to decide that Bio-Rad Laboratories Inc. retaliated against former general counsel Sanford “Sandy” Wadler for reporting FCPA violations.
The jury awarded Wadler $2.9 million in back pay and stock compensation and $5 million for punitive damages.… Continue Reading
Pleasure or pain? Voluntary FCPA disclosure and cooperation
Ben Haley and Jennifer Saperstein
March 9, 2015
In our recent report, Trends and Developments in Anti-Corruption Enforcement, we analyze major anti-corruption resolutions in 2014 and look ahead to what we expect in 2015.
As we explain in our report (pdf) (in Chinese here), 2014 was a year in which the benefits of voluntary disclosure and cooperating in U.S.… Continue Reading
Avon disgorgement lands on top ten list
Richard L. Cassin
December 26, 2014
Image courtesy of AvonAvon’s $135 million settlement with the DOJ and SEC earlier this month included a disgorgement to the SEC with interest that ranks 8th on our list of the biggest FCPA disgorgements.… Continue Reading
Vietnam puts Bio-Rad purchases under review, asks U.S. to share probe info
Richard L. Cassin
November 7, 2014
Image courtesy of Bio-Rad LaboratoriesVietnam’s Ministry of Health Thursday ordered a review of purchases of medical equipment manufactured by Seattle-based Bio-Rad Laboratories, Inc., following the company’s $55 million settlement of FCPA offenses, which included allegations of bribery in Vietnam.… Continue Reading
Bio-Rad cracks the disgorgement top ten list
Richard L. Cassin
November 4, 2014
Bio-Rad Laboratories paid a total of $55 million Monday to settle FCPA offenses. About $40 million of that went to the SEC as disgorgement. That payment landed tenth on our list of the biggest FCPA-related disgorgements.… Continue Reading
Bio-Rad pays $55 million to settle FCPA offenses
Richard L. Cassin
November 3, 2014
California-based life science company Bio-Rad Laboratories agreed Monday to pay a total of $55 million to settle DOJ and SEC allegations that subsidiaries made improper payments to foreign officials in Russia, Vietnam, and Thailand to win business.… Continue Reading
Bio-Rad lifts FCPA settlement reserve to $35 million
Julie DiMauro
March 21, 2014
Bio-Rad Laboratories Inc. said in its annual report Tuesday that it has added $15 million to its reserve for a potential Foreign Corrupt Practices Act settlement, bringing the total to $35 million.… Continue Reading
Job: Compliance Aggregation Analyst
FCPA Jobs
March 26, 2013
Job Title: Compliance Aggregation Analyst
Company: Bio-Rad
Location: Hercules, CA
Job Scope: Has global responsibility for aggregating and reporting to relevant regulators Bio-Rad’s spend data in and outside of the US, as required by state, federal, and foreign “Sunshine” regulations. … Continue Reading
Docs collect billions for drug promos
Richard L. Cassin
March 14, 2013
ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.
A Nashville psychiatrist led the pack, earning more than $1 million during the past four years for promotional talks and consulting for seven drug companies.… Continue Reading